National Defense Medical Center School of Nursing, Taipei, Taiwan.
Qual Life Res. 2010 Apr;19(3):307-15. doi: 10.1007/s11136-010-9596-6. Epub 2010 Feb 3.
This study examines the contributions of known predictors of survival and quality of life (QOL) to 1-year survival in ICD recipients.
This study used the data set from the antiarrhythmia versus implanted defibrillator (AVID) controlled clinical trial conducted by the National Institutes of Health, National Heart, Lung, and Blood Institute. The 507 patients randomly assigned to the ICD treatment were included in the analysis. Patients were mostly male (78.3%), with mean age of 64.85 +/- 10.81 and mean left ventricular ejection fraction of 32.2 +/- 13.45%. QOL was measured with the medical outcomes study 36-item short form health survey (SF-36) and quality of life index-cardiac version (QLI-CV). Data were analyzed with descriptive statistics and logistic regression.
Fifty-four (10.6%) patients died in the first year after ICD implantation. Angiotensin-converting enzyme inhibitor (ACE) medication, age, and QLI-CV were significant independent predictors of 1-year survival. The odds of survival of a younger patient with ACE medication and good QOL were approximately three times (OR = 3.96) greater than for an older patient, without ACE medication and with poor QOL.
Quality of life is an important factor predicting 1-year survival in patients with ICDs. ACE medication and younger age also predict 1-year survival independent of QOL and each other.
本研究旨在探讨已知预测生存和生活质量（QOL）的因素对 ICD 接受者 1 年生存率的贡献。
本研究使用了由美国国立卫生研究院、国家心脏、肺和血液研究所进行的抗心律失常与植入式除颤器（AVID）对照临床试验的数据组。507 名随机分配至 ICD 治疗的患者被纳入分析。患者主要为男性（78.3%），平均年龄为 64.85±10.81 岁，平均左心室射血分数为 32.2±13.45%。QOL 使用医疗结局研究 36 项简短健康调查（SF-36）和生活质量指数-心脏版本（QLI-CV）进行测量。数据分析采用描述性统计和逻辑回归。
在 ICD 植入后的第一年，有 54 名（10.6%）患者死亡。血管紧张素转换酶抑制剂（ACE）药物、年龄和 QLI-CV 是 1 年生存率的显著独立预测因素。服用 ACE 药物和 QOL 良好的年轻患者的生存几率大约是未服用 ACE 药物和 QOL 较差的老年患者的三倍（OR=3.96）。
生活质量是预测 ICD 患者 1 年生存率的重要因素。ACE 药物和年轻的年龄也独立于 QOL 预测 1 年生存率，彼此之间没有影响。
